



## Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

January 7, 2021

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.

The Company's presentation will be available on demand starting Monday, January 11<sup>th</sup>, 2021 at 6:00 AM ET, to those attending the conference virtually.

### About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting *Acinetobacter baumannii* infections), zoliflodacin (targeting *Neisseria gonorrhoeae* infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting *Pseudomonas* infections). For more information, visit [www.entasistx.com](http://www.entasistx.com).

### Entasis Company Contact

Kyle Dow  
Entasis Therapeutics  
(781) 810-0114  
[kyle.dow@entasistx.com](mailto:kyle.dow@entasistx.com)

### Investor Relations Contact

James Salierno  
The Ruth Group  
(646) 536-7028  
[jsalierno@theruthgroup.com](mailto:jsalierno@theruthgroup.com)

### Media Contact

Annika Parrish  
The Ruth Group  
(720) 412-9042  
[aparrish@theruthgroup.com](mailto:aparrish@theruthgroup.com)



Source: Entasis Therapeutics Holdings Inc.